Plexus Corp.'s SEC filings document operating results, financial condition, governance matters and material corporate events for its complex product design, manufacturing and services business. Recent 8-K reports furnish quarterly and fiscal-year earnings releases and related financial information for the company's product lifecycle operations across regulated end markets.
The filings also record shareholder meeting results, including director elections, advisory executive compensation votes and auditor ratification, as well as officer transition and compensation-arrangement disclosures. These records describe formal governance actions, executive roles and recurring public-company reporting obligations for PLXS.
Plexus Corp (PLXS) reports that President & CEO Todd P. Kelsey sold 1,500 shares of common stock on September 16, 2026 in a sale characterized as an open market or private transaction at $242.41 per share. Following this sale, he directly holds 64,388 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on November 20, 2025.
PLEXUS CORP (PLXS) reported that Sr. VP & CFO David Westen Abuhl exercised Restricted Stock Units into common stock on September 15, 2026. He converted 2,500 Restricted Stock Units granted under the Plexus Corp. 2024 Omnibus Incentive Plan into 2,500 shares of common stock, with 800 shares delivered or withheld for payment of exercise price or tax liability. Following this vesting event, 5,000 Restricted Stock Units remain directly held.
The vested units represented one third of the original RSU grant and were structured so that each unit represented a contingent right to receive one share of Plexus Corp. common stock, in a grant that qualifies under Rule 16b-3. No Rule 10b5-1 trading plan is reported for these transactions.
Plexus Corp (PLXS) director Karen Marie Rapp reported selling 500 shares of common stock on August 31, 2026 in an open-market or private transaction at $240.87 per share. After this sale, she directly holds 7,535 shares of Plexus common stock. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.
Plexus Corp. (PLXS) reports that its Board of Directors approved a new $100.0 million share repurchase program on August 20, 2026. This authorization will begin upon expiration of the company’s current $100.0 million repurchase program. As of August 19, 2026, the remaining balance under the current program was $9.6 million.
Plexus states it has no specific schedule or commitment for future repurchases and may buy back shares in amounts, at prices, and at times it deems appropriate, subject to market conditions, legal requirements, financing and other considerations.
PLEXUS CORP (PLXS) reported that President & CEO Todd P. Kelsey sold a total of 1,500 shares of common stock on August 19, 2026 in three open-market transactions. The sales were made at prices of $248.7887, $251.0850, and $252.2300 per share and were executed pursuant to a Rule 10b5-1 plan adopted on November 20, 2025. One transaction at $251.0850 per share reflects a weighted average sale price for trades executed in the range of $251.00 to $251.18 per share.
Plexus Corp. (PLXS) reports that President & CEO Todd P. Kelsey has filed a notice under Rule 144 to sell 4,500 shares of common stock through ROBERT W BAIRD & CO., with the shares coming from the vesting of Performance Stock Units on 02/11/2025 as compensation. Kelsey’s sales are being made pursuant to a trading plan adopted on November 20, 2025 and follow recent sales totaling several thousand shares between May and July 2026.
American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute for Medical Research report their beneficial ownership of Plexus Corp. common stock on an amended Schedule 13G. They collectively report beneficial ownership of 1,184,217 shares, representing 4.4% of the outstanding common stock of Plexus Corp.
The group has sole voting power over 1,051,902 shares and sole dispositive power over 1,184,217 shares, with no shared voting or dispositive power reported. The entities state that various investment company and institutional accounts advised by American Century Investment Management have the right to receive dividends and sale proceeds, and that no single client advised by American Century Investment Management owns more than 5% of the Plexus Corp. common stock.
Plexus Corp director Michael V. Schrock reported selling 4,000 shares of Plexus common stock on August 11, 2026, at a price of $275.00 per share. After this open-market sale, he directly holds 40,329 shares of Plexus common stock. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026.
Plexus Corp. reported strong top-line growth for the quarter ended July 4, 2026, with net sales of $1,304.8 million, up 28.1% year over year, and nine‑month sales of $3,538.4 million, up 19.0%. Gross margin held at 10.1%. Operating income rose to $61.3 million, but operating margin slipped to 4.7% as selling and administrative expenses increased, driven largely by $20.5 million of stock‑based compensation in the quarter, including $12.9 million from accelerated vesting tied to executive retirements. Net income was $43.0 million versus $45.1 million a year earlier, and diluted EPS was $1.58 versus $1.64, as the effective tax rate climbed to 23.8% due to a new global minimum tax and the absence of a prior‑year discrete tax benefit. For the first nine months, net income rose to $134.0 million and diluted EPS to $4.90.
Growth was broad-based: AMER and APAC sales increased 37.2% and 30.4% in the quarter, while Industrial and Aerospace/Defense sectors grew 42.2% and 27.1%. Cash and restricted cash were $314.6 million and total debt, finance lease and other obligations were $275.5 million. Operating cash flow was $39.0 million and free cash flow was negative $35.3 million, reflecting higher inventories to support program ramps and increased accounts receivable. The company repurchased 341,799 shares for $63.6 million under its 2026 authorization, with $21.4 million of capacity remaining, and reported after‑tax ROIC of 14.9% versus a 9.0% WACC.